Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

Official record

Identifier

NCT07529808

Recruiting locations

country

United States

Interventions studied

BHB810

Lead sponsor

BigHat Biosciences, Inc.

Target enrolment

164 participants

Study type

INTERVENTIONAL

Phase

Phase 1/2

Status

Recruiting

First posted

Apr 14, 2026

Last updated on the registry

Sep 29, 2026

Age

18 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
* Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.

  * Participants in Phase 1 Backfill Cohorts \& Phase 2 must be CDH17-positive by central testing.
  * Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.
* At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
* Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.
* Adequate organ and marrow function as defined in the protocol

Exclusion Criteria:

* Prior cancer treatment as follows, relative to the first planned dose of trial intervention:

  * Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)
  * Monoclonal antibody-based therapy (including ADCs) within 4 weeks
  * Immune checkpoint inhibitors within 4 weeks
  * Wide-field radiation therapy (\>30% marrow-bearing bones) within 4 weeks or \< 2 weeks of focal palliative radiation to nontarget lesions
* Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)
* Known hypersensitivity or allergic reaction to BHB810 or it's excipients
* Left ventricular ejection fraction \<50% or history of congestive heart failure Class III/IV
* QTc interval \> 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT/QTc
* Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant
* Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.
* Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention
* Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.

Indexed under

Pancreatic Cancer